Scott M. Wasserman

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

In our trial, inhibition of PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels to a median of 30 mg per deciliter (0.78 mmol per liter) and r...

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in ...

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients

clinicaltrials.gov Identifier: NCT01813422.

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

At 52 weeks, evolocumab added to diet alone, to low-dose atorvastatin, or to high-dose atorvastatin with or without ezetimibe significantly reduced LDL cholesterol levels in pat...

Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance

Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia

clinicaltrials.gov Identifier: NCT01763866.

Anti-PCSK9 Monotherapy for Hypercholesterolemia

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial